Menu
Recruiting NCT07027033

Nutritional Oleic Acid Modulation of adIpose Cholesterol Metabolism in Patients Living With Obesity

No phase Interventional Obesity Visceral Adipose Tissue White Adipose Tissue Inflammation Subcutaneous Adipose Tissue

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: acid-rich sunflower oil oleic acid, conventional sunflower oil.
Who it may be relevant to
Registry conditions: Obesity, Visceral Adipose Tissue, White Adipose Tissue Inflammation, Subcutaneous Adipose Tissue. Basic parameters: 18 years — 60 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Disruption of white adipose tissue (WAT) homeostasis during obesity is central to the development of associated cardiometabolic complications. Dietary supplementation with oleic acid in obese patients can limit these complications. Experimental data, obtained in preclinical models, suggest that the beneficial effects of oleic acid may protect the TAB by increasing cholesterol esterification. The NAMICO study aims to test this hypothesis using TAB biopsies collected from obese patients undergoing bariatric surgery who had previously undergone dietary enrichment with either a conventional oil or an oil rich in oleic acid.

Interventions

  • Other acid-rich sunflower oil oleic acid
    Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of sunflower oil rich in oleic acid
  • Other conventional sunflower oil
    Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of conventional sunflower oil

Primary outcome measures

  • Evaluate the effect of consuming oleic acid-rich sunflower oil versus conventional sunflower oil on cholesterol esterification within visceral white adipose tissue. [Time frame: 13 weeks +/- 2 week]

Eligibility criteria

Inclusion criteria

  • • Individual who has given informed consent.
  • Female adult aged between 18 and 60 years (included).
  • Patient with obesity at inclusion, meeting the HAS criteria for bariatric surgery eligibility: BMI ≥ 35 kg/m² associated with a comorbidity or BMI > 40 kg/m².
  • European origin: For this pilot study, we need to reduce variability factors and focus the research on women of European descent only (having both parents identified by the patient as of European origin).
  • Effective contraception if sexually active, or abstinence, or menopause (criterion required for bariatric surgery).
  • Presenting at inclusion with at least two clinical criteria of insulin resistance according to the definition of the International Diabetes Federation (IDF):
  • Dysglycemia (fasting glucose ≥ 100 mg/dL, glucose intolerance, or type 2 diabetes).
  • Hypertension (≥ 130/85 mm Hg).
  • Low HDL-cholesterol (< 50 mg/dL).
  • Elevated triglycerides (≥ 150 mg/dL).
  • Affiliated with a social security system or a beneficiary of such a system.
  • Bariatric surgery performed at Nantes University Hospital (CHU de Nantes).

Exclusion criteria

  • • Modification of diabetes treatment within the past month.
  • Ongoing or planned insulin therapy before bariatric surgery.
  • Modification of lipid-lowering treatment within the past three months.
  • Systemic corticosteroid therapy.
  • Antiviral therapy (HIV).
  • Dietary supplementation affecting lipid metabolism, including proactive margarine, Danacol, polyunsaturated fatty acid supplementation, or any other substance identified by the investigator.
  • Exocrine pancreatic insufficiency.
  • Pregnancy or breastfeeding.
  • History of organ transplantation.
  • Individual deprived of liberty or under legal protection (guardianship or trusteeship).
  • Any clinical condition in which the investigator considers that inclusion in the study may harm the patient's health or compromise the proper conduct of the study.
  • Participation in other clinical trials, except for non-interventional studies and research on surgical techniques or postoperative strategies.
  • Type I, monogenic or secondary diabetes.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Other

Study locations

France · 1 center
  • CHU de Nantes — Nantes

Identifiers

NCT: NCT07027033 · RC24_0626 · 2024-A02770-47

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗